iBio Inc (IBIO)
2.67
0.00 (0.00%)
USD |
NYAM |
Nov 04, 16:00
2.66
-0.01
(-0.37%)
Pre-Market: 20:00
iBio Research and Development Expense (Annual): 5.185M for June 30, 2024
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| June 30, 2024 | 5.185M |
| June 30, 2023 | 10.33M |
| June 30, 2022 | 9.827M |
| June 30, 2021 | 9.989M |
| June 30, 2020 | 3.573M |
| June 30, 2019 | 5.474M |
| June 30, 2018 | 3.986M |
| June 30, 2017 | 4.117M |
| June 30, 2016 | 3.156M |
| Date | Value |
|---|---|
| June 30, 2015 | 3.495M |
| June 30, 2014 | -0.15M |
| June 30, 2013 | 3.431M |
| June 30, 2012 | 4.981M |
| June 30, 2011 | 3.084M |
| June 30, 2010 | 2.517M |
| June 30, 2009 | 0.7974M |
| June 30, 2008 | 0.55M |
| June 30, 2007 | 0.6732M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
3.573M
Minimum
2020
10.33M
Maximum
2023
7.780M
Average
9.827M
Median
2022
Research and Development Expense (Annual) Benchmarks
| NovaBay Pharmaceuticals Inc | 0.068M |
| Palatin Technologies Inc | 22.40M |
| Theriva Biologics Inc | 14.31M |
| Oragenics Inc | 15.49M |
| Nanoviricides Inc | 5.437M |